Mineralys Therapeutics, Inc.MLYSNASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank75
3Y CAGR-10.6%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-10.6%/yr
Quarterly compound
Percentile
P75
Within normal range
vs 3Y Ago
0.7x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 43.22% |
| Q3 2025 | 14.32% |
| Q2 2025 | 28.93% |
| Q1 2025 | -8.75% |
| Q4 2024 | 17.60% |
| Q3 2024 | 3.83% |
| Q2 2024 | 28.15% |
| Q1 2024 | 14.26% |
| Q4 2023 | 6.68% |
| Q3 2023 | -2.00% |
| Q2 2023 | 45.60% |
| Q1 2023 | 20.78% |
| Q4 2022 | 60.56% |
| Q3 2022 | 54.30% |
| Q2 2022 | 11.76% |
| Q1 2022 | 69.38% |
| Q4 2021 | 0.00% |